Evidence map›Paper›PMID 41686531›Full record

ArticleJournal of chromatographic science2026

Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma.

Yuan Chen, Tolulope Adebusuyi, Edwina Oppong, Edidiong Abraham, Yen Maroney Lawrence, Jing Ma, Dong Liang, San L Pham, Frank E McDonald, Alira Danaher and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chromatographic science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuan ChenCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Tolulope AdebusuyiCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Edwina OppongCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Edidiong AbrahamCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Yen Maroney LawrenceCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Jing MaCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Dong LiangCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
San L PhamDepartment of Chemistry, Emory University, 1515 Dickey Dr., Atlanta, GA 30322  USA.
Frank E McDonaldDepartment of Chemistry, Emory University, 1515 Dickey Dr., Atlanta, GA 30322  USA.
Alira DanaherCenter for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, 223 James P Brawley Dr SW, Atlanta, GA 30314, USA.
Daqing WuCenter for Cancer Research and Therapeutic Development and Department of Biological Sciences, Clark Atlanta University, 223 James P Brawley Dr SW, Atlanta, GA 30314, USA.
Huan XieCollege of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.ORCID 0000-0002-0591-5619

Funding

Targeted Nano-drug-delivery-systems of Frist-in-class Drugs for CRPC: PK/PD Evaluation and Combination TherapyU54MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI Creaque C Tyler · 2020 to 2026
$22.0M
Targeting chemoresistant prostate cancer with novel EED inhibitorsR01CA256058 · NCI · CLARK ATLANTA UNIVERSITY · PI DAQING WU · 2022 to 2026
$2.1M
Small-molecule therapy for metastatic castration-resistant prostate cancerR42CA217491 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2021 to 2022
$1.9M
NCI NIH HHS R01CA256058NCI NIH HHS R42CA217491NIMHD NIH HHS U54MD007590 (Project 1) (Wu)NIMHD NIH HHS U54 MD007605NIMHD NIH HHS U54MD007605
6 · The paper itself

Abstract

SLP-1A6 is a nicardipine-derived analog that modulates the embryonic ectoderm development/Enhancer of Zeste Homolog 2 axis and holds promise as novel therapeutics for castration-resistant prostate cancer (PCa). We report here the development and validation of a robust, sensitive and specific LC-MS/MS method for quantifying SLP-1A6 in rat plasma, as part of its preclinical investigation. The method demonstrated excellent linearity, precision, accuracy, extraction recovery and stability with negligent matrix effect over a 5-2500 ng/mL concentration range. The method was successfully applied for a single intravenous dose pharmacokinetic (PK) study in adult male Sprague-Dawley rats and the resulting PK parameters were comparable to those of nicardipine, indicating that SLP-1A6 retains the favorable PK profile of the parent compound while offering in vivo efficacy for chemoresistant PCa. These findings support the further preclinical development of SLP-1A6 to overcome chemoresistance in PCa.

Indexed as

Liquid Chromatography-Mass SpectrometryTandem Mass SpectrometryAnimalsDrug StabilityLinear ModelsMaleRatsRats, Sprague-DawleyReproducibility of ResultsSensitivity and Specificity

Identifiers

PMID41686531
PMCPMC13089522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.